Latest Insider Transactions at Selecta Biosciences Inc (SELB)
This section provides a real-time view of insider transactions for Selecta Biosciences Inc (SELB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SELECTA BIOSCIENCES INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SELECTA BIOSCIENCES INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 14
2025
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
4,022
+0.05%
|
$72,396
$18.0 P/Share
|
|
Jan 13
2025
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
16,945
+0.1%
|
$288,065
$17.32 P/Share
|
|
Jan 10
2025
|
Christopher M Jewell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,000
+12.59%
|
$27,000
$3.23 P/Share
|
|
Jan 06
2025
|
Blaine Davis Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,028
-4.08%
|
$64,448
$16.83 P/Share
|
|
Jan 06
2025
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
8,708
-4.09%
|
$139,328
$16.83 P/Share
|
|
Jan 06
2025
|
Emily English Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
906
-2.2%
|
$14,496
$16.83 P/Share
|
|
Jan 06
2025
|
Christopher M Jewell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,286
-2.35%
|
$20,576
$16.83 P/Share
|
|
Jan 06
2025
|
Milos Miljkovic Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
948
-2.61%
|
$15,168
$16.83 P/Share
|
|
Jan 06
2025
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,458
-3.8%
|
$39,328
$16.83 P/Share
|
|
Jan 03
2025
|
Blaine Davis Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,961
-3.85%
|
$63,376
$16.72 P/Share
|
|
Jan 03
2025
|
Carsten Brunn President and CEO |
SELL
Open market or private sale
|
Direct |
8,563
-3.87%
|
$137,008
$16.72 P/Share
|
|
Jan 03
2025
|
Emily English Chief Operations Officer |
SELL
Open market or private sale
|
Direct |
891
-2.12%
|
$14,256
$16.72 P/Share
|
|
Jan 03
2025
|
Christopher M Jewell Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,264
-2.26%
|
$20,224
$16.72 P/Share
|
|
Jan 03
2025
|
Milos Miljkovic Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
932
-2.5%
|
$14,912
$16.72 P/Share
|
|
Jan 03
2025
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,417
-3.6%
|
$38,672
$16.72 P/Share
|
|
Jan 02
2025
|
Patrick J Zenner Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+20.04%
|
-
|
|
Jan 02
2025
|
Blaine Davis Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+17.63%
|
-
|
|
Jan 02
2025
|
Emily English Chief Operations Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,100
+27.7%
|
-
|
|
Jan 02
2025
|
Christopher M Jewell Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,100
+22.32%
|
-
|
|
Jan 02
2025
|
Carsten Brunn President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
57,500
+20.62%
|
-
|
|
Jan 02
2025
|
Kemal Malik Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+23.35%
|
-
|
|
Jan 02
2025
|
Timothy A Springer Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+0.03%
|
-
|
|
Jan 02
2025
|
Timothy C Barabe Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+9.64%
|
-
|
|
Jan 02
2025
|
Murat Kalayoglu Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+0.51%
|
-
|
|
Jan 02
2025
|
Milos Miljkovic Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,000
+33.76%
|
-
|
|
Jan 02
2025
|
Nishan M De Silva Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+22.88%
|
-
|
|
Jan 02
2025
|
Carrie Smith Cox Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+14.26%
|
-
|
|
Jan 02
2025
|
Michael Singer Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,600
+3.42%
|
-
|
|
Jan 02
2025
|
Metin Kurtoglu Chief Technology Officer |
BUY
Grant, award, or other acquisition
|
Direct |
16,100
+19.34%
|
-
|
|
Dec 26
2024
|
Emily English Chief Operations Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,650
+22.79%
|
$22,950
$3.3 P/Share
|
|
Dec 26
2024
|
Michael Singer Director |
SELL
Bona fide gift
|
Direct |
20,000
-21.99%
|
-
|
|
Dec 23
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
5,181
+0.06%
|
$98,439
$19.0 P/Share
|
|
Dec 20
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
21,800
+0.26%
|
$392,400
$18.94 P/Share
|
|
Dec 19
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
25,208
+0.1%
|
$453,744
$18.22 P/Share
|
|
Dec 10
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
2,901
-5.38%
|
$69,624
$24.35 P/Share
|
|
Dec 10
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,901
+5.1%
|
$2,901
$1.41 P/Share
|
|
Dec 09
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
10,763
-9.12%
|
$269,075
$25.55 P/Share
|
|
Dec 09
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,763
+14.83%
|
$10,763
$1.41 P/Share
|
|
Nov 21
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
32,789
-39.12%
|
$524,624
$16.67 P/Share
|
|
Nov 21
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,789
+28.12%
|
$32,789
$1.41 P/Share
|
|
Nov 20
2024
|
Christopher M Jewell Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
14,000
+25.95%
|
$42,000
$3.23 P/Share
|
|
Nov 20
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
5,700
-5.03%
|
$96,900
$17.69 P/Share
|
|
Nov 20
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,700
+9.13%
|
$5,700
$1.41 P/Share
|
|
Nov 19
2024
|
Michael Singer Director |
SELL
Bona fide gift
|
Direct |
28,821
-24.07%
|
-
|
|
Nov 19
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
200
-0.39%
|
$3,800
$19.5 P/Share
|
|
Nov 19
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
200
+0.39%
|
$200
$1.41 P/Share
|
|
Nov 18
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
58,295
+0.34%
|
$1,049,310
$18.19 P/Share
|
|
Nov 18
2024
|
Metin Kurtoglu Chief Technology Officer |
SELL
Open market or private sale
|
Direct |
34,400
-22.65%
|
$619,200
$18.39 P/Share
|
|
Nov 18
2024
|
Metin Kurtoglu Chief Technology Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
34,400
+28.71%
|
$34,400
$1.41 P/Share
|
|
Nov 15
2024
|
Timothy A Springer Director |
BUY
Open market or private purchase
|
Direct |
277,246
+3.2%
|
$4,713,182
$17.09 P/Share
|